Skip to main content
Year archive

Oncopeptides — 2021 filings

All 55 regulatory filings released by Oncopeptides (ONCO) in 2021, sourced directly from the official regulator.

55 Filings
2021 Period
2021 filings (55)
Filing Released Lang
Interim / Quarterly Report 2021
Interim / Quarterly Report Q3 2021
2021-11-24 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q3 2021
2021-11-24 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-11-16 English
Jakob Lindberg appointed CEO of Oncopeptides
Board/Management Information
2021-11-15 English
Jakob Lindberg utnämnd till VD för Oncopeptides
Board/Management Information
2021-11-15 Swedish
Major Shareholding Notification 2021
Major Shareholding Notification
2021-11-09 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-11-05 English
Oncopeptides focuses clinical development efforts to increase cash runway
Legal Proceedings Report
2021-11-04 English
Oncopeptides fokuserar det kliniska utvecklingsprogrammet och förstärker kassan
Regulatory Filings
2021-11-04 Swedish
Major Shareholding Notification 2021
Major Shareholding Notification
2021-10-29 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-10-27 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-10-26 English
Oncopeptides drar tillbaka Pepaxto®, minskar organisationen och fokuserar på R&D
Legal Proceedings Report
2021-10-22 Swedish
Oncopeptides withdraws Pepaxto®[ ]in US, scale down organization and focus on R&D
Regulatory Filings
2021-10-22 English
Oncopeptides’ CFO Anders Martin-Löf will leave the company
Board/Management Information
2021-10-15 English
Oncopeptides CFO Anders Martin-Löf kommer att lämna bolaget
Board/Management Information
2021-10-15 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q2 2021
2021-08-19 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q2 2021
2021-08-19 English
Regulatory update from US Food and Drug Administration
Regulatory Filings
2021-07-28 English
Regulatorisk uppdatering från FDA
Regulatory Filings
2021-07-28 Swedish
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements
2021-07-21 English
Uppdaterade resultat från fas 3-studien OCEAN: melflufen nådde primära målet superioritet för PFS – överlevnadsdata leder till att rekryteringen av patienter i kliniska studier pausas
Regulatory Filings
2021-07-08 Swedish
Updated results from phase 3 OCEAN study shows melflufen met primary endpoint of superior PFS – Overall Survival data lead to partial clinical hold
Regulatory Filings
2021-07-08 English
Antal aktier och röster i Oncopeptides
Share Issue/Capital Change
2021-06-30 Swedish
Number of shares and votes in Oncopeptides
Declaration of Voting Results & Voting Rights Announcements
2021-06-30 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-06-02 English
Kommuniké från årsstämma i Oncopeptides AB (publ)
AGM Information
2021-05-26 Swedish
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
AGM Information
2021-05-26 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Q1 2021
2021-05-26 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q1 2021
2021-05-26 English
Phase 3 OCEAN study demonstrates that melflufen is at least as efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma
Regulatory Filings
2021-05-25 English
Fas 3-studien OCEAN visar att melflufen är minst lika effektivt som pomalidomid - det mest använda läkemedlet i relapserande refraktärt multipelt myelom
Regulatory Filings
2021-05-25 Swedish
Antal aktier och röster i Oncopeptides
Share Issue/Capital Change
2021-04-30 Swedish
Number of shares and votes in Oncopeptides
Declaration of Voting Results & Voting Rights Announcements
2021-04-30 English
Report Publication Announcement 2021
Report Publication Announcement
2021-04-26 Swedish
Report Publication Announcement 2021
Report Publication Announcement
2021-04-26 English
Annual General Meeting in Oncopeptides AB (publ)
AGM Information
2021-04-26 English
Årsstämma i Oncopeptides AB (publ)
AGM Information
2021-04-26 Swedish
Oncopeptides lämnar in ansökan om villkorat marknadsgodkännande för melflufen i EU
Regulatory Filings
2021-04-16 Swedish
Oncopeptides submits application for conditional marketing authorization of melflufen in the EU
Regulatory Filings
2021-04-16 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-04-12 English
Number of shares and votes in Oncopeptides
Share Issue/Capital Change
2021-03-31 English
Antal aktier och röster i Oncopeptides
Share Issue/Capital Change
2021-03-31 Swedish
Major Shareholding Notification 2021
Major Shareholding Notification
2021-03-12 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-03-11 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-03-10 English
Oncopeptides has completed a directed share issue raising approximately SEK 1,106 million (USD 130 million)
Capital/Financing Update
2021-03-10 English
Oncopeptides har genomfört en riktad nyemission om cirka 1 106 miljoner kronor (130 miljoner USD)
Capital/Financing Update
2021-03-10 Swedish
Oncopeptides intends to carry out a directed share issue
Capital/Financing Update
2021-03-09 English
Oncopeptides avser att genomföra en riktad nyemission
Capital/Financing Update
2021-03-09 Swedish
Oncopeptides får FDA-godkännande för PEPAXTO® för patienter med relapserande eller refraktärt multipelt myelom
Regulatory Filings
2021-02-26 Swedish
FDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma
Regulatory Filings
2021-02-26 English
Audit Report / Information 2020
Audit Report / Information FY 2020
2021-02-18 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report FY 2020
2021-02-18 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-01-27 English